Clinical trials: Autoimmune Bullous Disease
Bullous Pemphigoid
Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis
Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity.
- Trial name
- BP (NCT06213909)
- Testing
- This is a retrospective analysis of health data from inpatient record, no intervention was designed
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Xijing Hospital
Bullous Pemphigoid
Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid
The aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.
- Trial name
- Rituximab2 (NCT00525616)
- Testing
- Mabthera
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid
Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.
Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and conflict the exclusion criteria will receive NPB-01(intravenous…
- Trial name
- NPB-01 (NCT00809822)
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Bullous Pemphigoid
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.
- Trial name
- NCT05906706
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Pemphigus
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus is a severe autoimmune blistering disease mediated by circulating antibodies against certain proteins important for maintaining skin integrity.
- Trial name
- NCT00656656
- Testing
- Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University of Luebeck
Bullous Pemphigoid
Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disorder most commonly affecting the older population between 60-80 years old.
- Trial name
- NCT05984381
- Testing
- Prednisolone, Dapsone, Methotrexate
- Where
- India
- Volunteers
- 62 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Bullous Pemphigoid
Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid
Bullous pemphigoid (BP) is the most frequent autoimmune skin disease and mainly affects elderly individuals. BP classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense…
- Trial name
- BP-IL17RB (NCT06479018)
- Testing
- Blood sampling, Liquid bubble sampling, Cutaneous biopsy
- Where
- France
- Volunteers
- 140 people
- Sponsor
- CHU de Reims
Pemphigoid, Bullous, Adrenal Insufficiency
Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)
The braking of the corticotropic axis is well established during the induction phase of superpotent topical corticosteroid therapy (clobetasol propionate) in bullous pemphigoid (BP).
- Trial name
- PB-DEPIST (NCT06148090)
- Testing
- clobetasol decreasing measurement
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Methemoglobinemia, Linear IgA Bullous Dermatosis
Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration
The objectives of the study are to evaluate pharmacokinetics, distribution in blood leucocytes, metabolism and methemoglobinemia after single-dose and repeated-dose administration of 100 mg of dapsone in healthy subjects…
- Trial name
- NCT02493283
- Testing
- Dapsone single dose, Dapsone multiple dose, leucocytes
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Pemphigoid, Bullous
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
- Trial name
- NCT02226146
- Testing
- Bertilimumab
- Where
- 8 sites in United States, Israel
- Volunteers
- 11 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Bullous Pemphigoid
Rituximab in the Treatment of Patients With Bullous Pemphigoid
This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
- Trial name
- NCT00286325
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Bullous Pemphigoid
Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients
Bullous pemphigoid affects mainly elderly patients. It is often associated with neurologic disorders, which represent a major risk factor of the disease
- Trial name
- NCT03320798
- Testing
- Data record
- Where
- France
- Volunteers
- 178 people
- Sponsor
- CHU de Reims
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Bullous Pemphigoid (BP)
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
Bullous pemphigoid (BP) is the most common of the autoimmune blistering skin diseases in Western Europe. [Joly 2012]The study will recruit the new onset or relapsing mild to moderate BP patients.
- Trial name
- NCT04035733
- Testing
- rVA576
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 9 people
- Sponsor
- AKARI Therapeutics
Bullous Pemphigoid
Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids
Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01…
- Trial name
- NCT01408550
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autoimmune Bullous Dermatosis
Coagulopathy of Immunodermatologic Diseases
This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and…
- Trial name
- NCT06037187
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Bullous Pemphigoid
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
The purpose of this study is to evaluate the safety of efgartigimod PH20 SC over a longer period of time in adult participants with moderate-to-severe bullous pemphigoid (BP) who have completed ARGX-113-2009 study.
- Trial name
- BALLAD+ (NCT05681481)
- Testing
- efgartigimod PH20 SC, Prednisone
- Where
- 40 sites in United States, Australia and 15 more
- Volunteers
- 64 people
- Sponsor
- argenx
Bullous Pemphigoid
Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
The study is an observational, multi-center, prospective, non-interventional and open-label data collection study assessing outcomes, treatment patterns, adverse events and costs in patients diagnosed with bullous pemphigoid.
- Trial name
- EDP-PB (NCT02837965)
- Testing
- treatment with topical superpotent corticosteroid therapy, treatment with systemic therapy (methotrexate), treatment systemic therapy (prednisone)
- Where
- France
- Volunteers
- 149 people
- Sponsor
- CHU de Reims
Bullous Pemphigoid (BP)
Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate…
- Trial name
- NCT07210554
- Testing
- Stapokibart injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.